Table 5: The impact of 1,25(OH)2D3 and MTX cotreatment on inflammation-related cytokines in the RA and healthy control group.

RANKL 
(pmol/L)
OPG 
(pmol/L)
RANKL/OPGTNF-
(pg/mL)
IL-17 
(pg/mL)
IL-6 
(pg/mL)
IL-4 
(pg/mL)

RA patient
 Anti-CD3/CD28100.72 ± 11.980.57 ± 0.15190.24 ± 51.25508.52 ± 90.94606.76 ± 49.797939.02 ± 2108.859.46 ± 4.15
 D2M291.60 ± 10.470.54 ± 0.13174.64 ± 31.68294.4 ± 97.24341.53 ± 58.683464.63 ± 2061.3920.82 ± 13.50
Healthy control
 Anti-CD3/CD2883.09 ± 12.170.61 ± 0.07136.23 ± 13.42195.95 ± 52.83249.87 ± 17.632607.90 ± 232.986.77 ± 4.43
 D2M270.44 ± 13.010.52 ± 0.43136.28 ± 27.89151.48 ± 32.21197.98 ± 43.972427.27 ± 238.1310.73 ± 5.59

Values are expressed as mean ± standard deviation.